# Charles River Laboratories

Type: Company (CRL)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/charles-river-laboratories
Canonical HTML page: https://getfinancebrief.com/entity/charles-river-laboratories

## Recent coverage (1 stories)

### Morgan Stanley cuts IQV to $200, lifts CRL to $220 on biotech funding divide
2026-06-19 02:34:00 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Morgan Stanley’s June 17 split decision on CRL and IQV reshapes CRO stock valuations. The upgrade to Overweight on Charles River and downgrade of IQVIA reflect a diverging view on exposure to the biotech capital cycle, with clear price target adjustments and implications for sector rotation.
Full story: https://getfinancebrief.com/story/morgan-stanley-crl-upgrade-iqv-downgrade-stocks

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.